海利生物(603718.SH)完成註銷上海冉裕科技合夥企業(有限合夥)
格隆匯1月6日丨海利生物(603718.SH)公佈,2019年8月20日,公司召開第三屆董事會第十三次會議審議通過了《關於上海冉裕科技合夥企業(有限合夥)清算並註銷的議案》。公司董事會授權公司經營層按照法定程序辦理上海冉裕科技合夥企業(有限合夥)涉及的所有清算、註銷事宜。
2020年1月6日,公司收到上海市奉賢區市場監督管理局出具的《准予合夥企業登記決定書》,准予上海冉裕科技合夥企業(有限合夥)的註銷登記申請,上海冉裕科技合夥企業(有限合夥)的工商註銷登記手續已全部辦理完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.